CEO Kevin Ali Marks Organon’s Progress In First Post-Spin Year

Women’s Health Build-Up Continues Through Deals

 
• By Mandy Jackson

A year after Organon spun out of Merck, the company has delivered on its financial guidance, generated double-digit biosimilars sales growth and executed six deals to grow in women’s health.

Three white checkmarks on multicolored toy circles in a row in the middle on bright aqua blue background
Ali highlighted progress across all three Organon businesses – established brands, biosimilars and women's health • Source: Shutterstock

More from Strategy

More from Business